Archived Medical News Stories

RSSArchived Drug Trial News Stories - August 2012

Date Title Comments Rating
2012-08-31 VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody 0 None
2012-08-31 Elan commences ELND005 Phase 2 study in Bipolar I Disorder 0 None
2012-08-31 Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans 0 None
2012-08-31 Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors 0 None
2012-08-31 Sosei’s QVA149 Phase III study on COPD meets primary endpoint 0 None
2012-08-30 IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus 0 None
2012-08-30 Combination of POZEN’s PA32540 and clopidogrel results in greater antiplatelet effects 0 None
2012-08-30 Protalex announces results from PRTX-100 Phase 1b trial on active rheumatoid arthritis 0 None
2012-08-30 Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain 0 None
2012-08-30 Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma 0 None
2012-08-30 Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C 1 None
2012-08-30 Lilly decides to terminate pomaglumetad methionil Phase III trial on schizophrenia 0 None
2012-08-30 Elan commences ELND005 Phase 2 study in Bipolar I Disorder 0 None
2012-08-29 Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals 0 4.5
2012-08-29 Omitting aspirin leads to less bleedings but does not increase risk of stent thrombosis, MI 0 None
2012-08-29 Taking aspirin associated with reduced risk of death from prostate cancer 0 None
2012-08-29 Esperance completes EP 100 and paclitaxel Phase 2 combination trial on advanced ovarian cancer 0 None
2012-08-29 Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer 0 None
2012-08-29 Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis 0 4.5
2012-08-28 Eplerenone shown to reduce cumulative heart failure hospitalisations 0 None
2012-08-28 Aeterna Zentaris commences enrollment in AEZS-130 Phase 2A trial for cancer cachexia 0 None
2012-08-28 Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at ERS Annual Congress 0 None
2012-08-28 Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia 0 None
2012-08-28 Global platelet reactivity effectively identifies ACS patients at high risk of ischemic events 0 None
2012-08-28 Copeptin estimates prognosis in patients with heart failure 0 None
2012-08-28 Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment 0 None
2012-08-28 Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI 0 None
2012-08-28 Morphotek commences MORAb-004 Phase II metastatic soft tissue sarcoma trial 0 None
2012-08-28 America Stem Cell commences ASC-101 Phase I/II study in hematologic malignancies 0 None
2012-08-28 Neuralstem completes NSI-566 Phase I trial on amyotrophic lateral sclerosis 0 None
2012-08-27 Insulin glargine retards progression of atherosclerosis in high-risk people 0 None
2012-08-27 Update on Merck's development programs for vorapaxar, ER niacin/laropirprant and anacetrapib 0 5
2012-08-27 Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease 0 None
2012-08-27 Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides 0 4
2012-08-27 Spironolactone should be considered as a treatment option in hypertensive patients with DHF 0 None
2012-08-27 Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty 0 None
2012-08-27 New data from Boehringer Ingelheim and Pfizer's tiotropium clinical studies on asthma, COPD 0 None
2012-08-27 LCZ696 demonstrates beneficial effects in heart failure patients with preserved ejection fraction 0 None
2012-08-27 Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer 0 None
2012-08-27 Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death 0 None
2012-08-24 Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC 0 None
2012-08-24 Lilly’s solanezumab Phase 3 trials on AD do not meet primary endpoints 0 None
2012-08-24 Dartmouth’s professor shares news of DAR-901 TB vaccine development 0 None
2012-08-24 Pre-emptive therapy better than valacyclovir prophylaxis in treating CMV in transplant recipients 0 None
2012-08-24 Diabetes journal reports results from novel experimental therapy 0 None
2012-08-24 Bristol-Myers Squibb terminates BMS-986094 Phase II development for treatment of hepatitis C 0 None
2012-08-24 Results from Biodesix VeriStrat phase II advanced lung cancer trials 0 None
2012-08-24 NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K. 0 None
2012-08-24 AcelRx commences third ARX-01 Phase 3 study in post-operative pain 0 None
2012-08-23 Aeras, IDRI announce start of first ID93 + GLA-SE Phase I trial for tuberculosis 0 None
2012-08-22 Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia 0 None
2012-08-22 CIRT to determine whether methotrexate can reduce heart attacks, strokes and CVD deaths 0 None
2012-08-22 PhaseBio commences Glymera Phase 2b study in type 2 diabetes 0 None
2012-08-21 Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease 0 None
2012-08-21 DPT Labs, Imprimis sign agreement to commence work on Impracor clinical supplies 0 None
2012-08-21 MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos 0 4
2012-08-21 Medivir initiates MIV-711 phase Ib trial in healthy volunteers 0 None
2012-08-21 Daily vitamin D intake protects against respiratory infections in children 0 None
2012-08-21 Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma 0 None
2012-08-20 BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers 0 None
2012-08-20 ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan 0 None
2012-08-20 Enrollment complete in BDSI's pivotal pharmacokinetic study of BNX for opioid dependence 0 None
2012-08-20 Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure 0 None
2012-08-18 FibeBiotics aims to prove benefits of polysaccharides in clinical trials 0 None
2012-08-17 Promising new treatment for bronchiectasis 0 None
2012-08-17 Montelukast improves respiratory disturbance and adenoid size in children with OSA 0 4
2012-08-17 Enzalutamide drug extends survival in people with advanced prostate cancer 0 None
2012-08-17 Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA 0 None
2012-08-16 Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis 0 1
2012-08-16 Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer 0 None
2012-08-16 Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial 0 None
2012-08-16 Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor 0 None
2012-08-16 Genocea commences GEN-003 Phase 1/2a study in moderate-to-severe HSV-2 infection 0 None
2012-08-16 3SBio files APX001 IND application with SFDA in China 0 None
2012-08-15 Recognizing the role of international partnerships in global health 0 None
2012-08-15 Proteonomix receives FDA approval to commence UMK-121 Phase 1 trial in end-stage liver disease 0 None
2012-08-15 FDA requests Biovest to conduct second Phase III trial of BV301 for NHL 0 None
2012-08-15 Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer 0 None
2012-08-15 Compounds in cocoa may help decrease blood pressure 0 None
2012-08-14 Vandetanib given for advanced differentiated thyroid cancer almost doubles progression free survival 0 None
2012-08-14 Latrepiridine reduces level of at least two neurodegeneration-related proteins in mice 0 None
2012-08-13 CBIS initiates CS-TATI-1 GMP development plan 0 None
2012-08-13 Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis 0 None
2012-08-13 Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS 0 None
2012-08-13 NIH awards ADi Phase II SBIR grant to scan Plasmodium falciparum proteome for protective antigens 0 5
2012-08-13 Orally effective FluCide anti-influenza drug candidate 0 None
2012-08-12 Study assesses gender differences in the efficacy of antiretroviral treatment 0 None
2012-08-12 Combination of novel drug therapy and PSA test can effectively detect prostate cancer 0 None
2012-08-12 Daily aspirin use may reduce overall cancer mortality 0 None
2012-08-12 Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC 0 None
2012-08-12 PharmAthene receives clinical hold order from FDA for SparVax rPA anthrax vaccine program 0 None
2012-08-09 Herceptin® could potentially be delivered via a standard injection 0 None
2012-08-09 Clinical trials to test safety of 3K3A-APC in patients with ischemic stroke 0 None
2012-08-09 Combination of two existing pharmaceutical drugs shows promise against cocaine addiction 0 None
2012-08-09 Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication 0 None
2012-08-09 Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS 1 5
2012-08-09 Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer 0 None
2012-08-09 Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder 0 None
2012-08-08 Omeros completes enrollment in first of two OMS103HP Phase 3 meniscectomy trials 0 None
2012-08-08 HCRI announces successful completion of randomization in DAPT Study 0 None
2012-08-08 Patients in clinical trials of new targeted cancer therapies appear to have lower risk of side-effects 0 None
2012-08-08 Corticosteroids show no clinical benefit in treating acute sinusitis 0 None
2012-08-08 UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial 0 None
2012-08-07 Clinical trial targets breast cancer cells by injecting trastuzumab directly into the spinal fluid 0 None
2012-08-07 Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors 0 None
2012-08-07 Adalimumab effective in maintaining remission in pediatric patients with Crohn's disease 0 None
2012-08-07 Creatine may fight major depression in women 0 5
2012-08-07 Topline results from Janssen bapineuzumab Phase 3 trial on mild-to-moderate Alzheimer's 0 None
2012-08-06 Curemark receives FDA clearance for enrollment of children aged 9-12 in CM-AT study for autism 0 None
2012-08-06 Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors 0 None
2012-08-06 Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients 0 None
2012-08-06 Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma 0 None
2012-08-06 TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes 0 None
2012-08-03 Caffeine may ease movement symptoms of Parkinson's 0 None
2012-08-03 Healthpoint Biotherapeutics announces results from HP802-247 Phase 2b trial on venous leg ulcers 0 None
2012-08-02 Combination of sitagliptin and lansoprazole offers clinical benefits for T1D patients 0 None
2012-08-02 Investigational drug shows promise against most severe form of congenital hyperinsulinism 0 None
2012-08-02 Combination hormonal therapy improves survival in advanced breast cancer 0 None
2012-08-02 Combination of anastrozole and fulvestrant extends survival in women with metastatic breast cancer 0 None
2012-08-02 Caffeine may help control movement in people with Parkinson's 0 None
2012-08-01 Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner 1 2.7
2012-08-01 Teplizumab type I diabetes prevention study now enrolls younger children 0 None

Total

122 posts
3 comments
17 raters